Asset profile
Nusinersen · Spinraza
RNA / oligonucleotide
Evidence outlook
Approved: Spinal Muscular Atrophy
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
2 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 2 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Nusinersen (Spinraza): this drug | Approved | RNA / oligonucleotide | — | ||
| Apitegromab | Phase 3 | Monoclonal antibody | Activin/myostatin type II receptor | ||
| Taldefgrobep Alfa | Phase 3 | Antibody-derived scaffold | Activin/myostatin type II receptor |
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (2)
2028 (1)
November 2028 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.